Companies in the I-direct pharma universe reported muted Q2 numbers as a challenging environment in the US generic space continued to weigh despite a recovery in domestic formulations post GST implementation. The revenues of the universe were at | 38621 crore, almost flat YoY. EBITDA for the universe declined ~14% YoY to | 8242 crore mainly due to pricing pressure and high base of exclusivities in the US. However, an improvement in domestic margins, cost control and curb in R&D; spending restricted a further fall in margins....